Peter H. O’Donnell, MD, on Pembrolizumab for Cisplatin-Ineligible Patients With Advanced Urothelial Cancer

Posted: Wednesday, July 7, 2021

Peter H. O’Donnell, MD, of The University of Chicago, discusses implications of results from the KEYNOTE-052 trial, which showed the benefit of first-line pembrolizumab for cisplatin-ineligible patients with advanced disease, his own clinical experience with the therapy, and what the future of this treatment might be.